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Abstract
Background Prucalopride, a selective, high-affinity
5-hydroxytryptamine 4 receptor agonist, stimulates gas-
trointestinal and colonic motility and alleviates common
symptoms of chronic constipation (CC) in adults. The
relative efficacy by gender has not been evaluated.
Aim To evaluate the global efficacy and safety of
prucalopride 2 mg daily in men and women with CC using
data from six large, randomized, controlled clinical trials.
Methods Data were combined from six phase 3 and 4,
double-blind, randomized, placebo-controlled, parallel-
group trials. The primary efficacy endpoint was the per-
centage of patients with a mean of C3 spontaneous com-
plete bowel movements (SCBMs) per week over 12 weeks
of treatment. Safety was assessed throughout all the trials.
Results Overall, 2484 patients (597 men; 1887 women;
prucalopride, 1237; placebo, 1247) were included in the
integrated efficacy analysis and 2552 patients were inclu-
ded in the integrated safety analysis. Significantly more
patients achieved a mean of C3 SCBMs/week over the
12 weeks of treatment in the prucalopride group (27.8 %)
than in the placebo group [13.2 %, OR 2.68 (95 % CI 2.16,
3.33), p\ 0.001]. Prucalopride had a favorable safety and
tolerability profile. Efficacy and safety outcomes were not
significantly different between men and women.
Conclusion The integrated analysis demonstrates the
efficacy and safety of prucalopride in the treatment of CC
in men and women.
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Abbreviations
ANCOVA Analysis of covariance
BM Bowel movement




FoTA Final on-treatment assessment
HAPC High-amplitude propagating contraction
5-HT4 5-Hydroxytryptamine 4
NNT Number needed to treat
PAC-QOL Patient Assessment of Constipation Quality
of Life questionnaire
PAC-SYM Patient Assessment of Constipation
Symptoms questionnaire
QTcB QT interval corrected according to Bazett’s
formula
QTcF QT interval corrected according to
Fridericia’s formula
SAS Statistical Analysis System
SBM Spontaneous bowel movement
SCBM Spontaneous complete bowel movement
SD Standard deviation
TEAE Treatment-emergent adverse event
Introduction
Chronic constipation (CC) is a common disorder that can
significantly impair an individual’s health-related quality
of life [1] and work productivity [2]. Although laxatives
may provide short-term symptom relief [3], most currently
available laxatives do not directly target the underlying
causes of constipation, such as lack of effective propulsive
contractile activity possibly related to impaired intrinsic
neural mechanisms [4–9], and are unable to provide relief
from associated symptoms such as bloating, incomplete
evacuation, and lumpy or hard stools [10]. Unfortunately,
device-based treatments, such as those that stimulate the
sacral nerve, have not been efficacious [11], but there are
several pharmacological treatment options for patients with
CC [12]. 5-Hydroxytryptamine 4 (5-HT4) receptor agonists
have been shown to be effective in enhancing propulsive
intestinal motility [13]; however, non-selective agents such
as cisapride and tegaserod have been associated with
adverse cardiovascular events, possibly owing to interac-
tion with other 5-HT receptors [14]. Prolongation of the QT
interval has been associated with interaction between
5-HT4 receptor agonists and human ether-a`-go-go-related
gene (hERG) potassium channels [15]. Prucalopride is a
selective, high-affinity 5-HT4 receptor agonist that does not
exhibit a clinically relevant affinity for hERG channels [15,
16].
Prucalopride has been approved in the European Union
for the symptomatic treatment of CC in adults in whom
laxatives have failed to provide adequate relief [17]. The
efficacy and safety of prucalopride has been investigated
in five large phase 3 trials and one phase 4 trial in
patients with CC [18–23]. In this integrated analysis, the
efficacy and safety of prucalopride at doses of up to
2 mg/day was evaluated across all six clinical trials in
both genders. Analysis of this large pooled data set pro-
vides an overview of the efficacy and safety of prucalo-
pride in both men and women across four continents. This
analysis also aims to compare the treatment response and
safety of prucalopride in men versus women, and to
investigate the response in individuals with severe CC at
baseline.
Methods
This integrated analysis of efficacy and safety was performed
using combined data from six phase 3 and 4, multicenter,
double-blind, randomized, placebo-controlled, parallel-group
trials performed across three continents [ClinicalTrials.gov
identifiers: SPD555-302 (NCT01147926), SPD555-401
(NCT01424228), PRU-CRC-3001 (NCT01116206), PRU-
USA-13 (NCT00485940), PRU-USA-11 (NCT00483886),
and PRU-INT-6 (NCT00488137)]. These trials were
approved by independent Institutional Review Boards or
independent Ethics Committees and were conducted in
compliance with the Declaration of Helsinki, Good Clinical
Practice guidelines, and applicable regulatory requirements.
Patients provided written informed consent before entering
the trials.
The study designs of these trials were similar (Table 1)
and have been described in further detail in the published
literature [18–23]. All trials included adult patients with
CC [defined as B2 spontaneous bowel movements (SBMs)
per week for at least 6 months]. In addition, participants
had to have hard or very hard stools, a sensation of
incomplete evacuation, or straining during defecation in at
least 25 % of bowel movements (BMs). Patients were
excluded if they were considered to have drug-induced
constipation, or constipation secondary to causes such as
endocrine, metabolic, or neurological disorders, or surgery.
The doses of prucalopride used in the trials varied from 1 to
4 mg/day; the approved 2 mg/day dose was evaluated in all
of the trials (Table 1). Only patients receiving prucalopride
2 mg/day and the few individuals who received prucalo-
pride 1 mg/day throughout a trial were included in this
integrated analysis.
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Efficacy
In each of the six trials, efficacy data were collected from
patient diaries that recorded medication intake, stool fre-
quency, and stool characteristics on a daily basis
throughout the treatment period.
The primary efficacy endpoint for this integrated anal-
ysis was the percentage of patients with a mean frequency
of C3 spontaneous complete bowel movements (SCBMs)
per week over weeks 1–12.
The secondary efficacy endpoints included the fol-
lowing: BM frequency; stool characteristics; time to first
BM; rescue medication use; Patient Assessment of Con-
stipation Symptoms questionnaire (PAC-SYM) and
Patient Assessment of Constipation Quality of Life
questionnaire (PAC-QOL) scores; and global severity of
constipation and global efficacy of treatment scores.
Bisacodyl was the protocol-specified rescue medication
(laxative) used during each of the trials. We also assessed
the mean number of tablets taken or enemas administered
Table 1 Description of the six randomized, double-blind, placebo-controlled clinical trials
Study ID Number of study centers and
location







































Belgium, Czech Republic, Hungary,


























































































12 66/650 43.0 (17–89)
The primary endpoint for each trial was the proportion of patients with C3 SCBMs/week over the duration of the trial
SCBM spontaneous complete bowel movement
a Prucalopride and placebo administered as oral tablets
b Patients receiving prucalopride 4 mg were not included in the integrated analysis
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per week and the mean number of days on which any
laxative was used.
In an exploratory analysis, the proportions of patients
meeting the primary endpoint who had no SBMs at base-
line were compared with those who had one or more SBM
at baseline.
Safety
The following safety parameters were monitored through-
out the trials: adverse events, clinical laboratory evalua-
tions (hematology, biochemistry, and urinalysis),
electrocardiogram (ECG) parameters, and vital signs. Full
details of the safety protocols are published elsewhere [18–
23].
Statistical Analysis
Data from the six trials were combined. Statistical analyses
and tests were performed on the combined efficacy data.
Safety data were evaluated descriptively only. Statistical
analysis was performed using Statistical Analysis System
(SAS) version 8 (SAS Institute, Cary, NC, USA). In studies
SPD555-302 and SPD555-401, patients in the prucalopride
group who were aged C65 years started on a daily dose of
1 mg, in line with the approved starting dose for this age
group. However, the prucalopride dose was increased to
2 mg/day in the majority of these patients during the
studies, so the results were combined into a single group
(prucalopride B2 mg/day) for the current analysis.
Primary Endpoint
The Cochran–Mantel–Haenszel test was used to compare
the effects of treatment on the primary endpoint. The
analysis was stratified by study number, number of com-
plete bowel movements (CBMs) per week at baseline (0 or
[0), geographical region, and sex. All tests were per-
formed at a 5 % level of significance. Odds ratios [with
95 % confidence intervals (CIs)] for each trial were derived
and presented in a forest plot. Inconsistency between trials
was evaluated using the I2 statistic and the Breslow–Day
test [24].
Data Imputation for Primary Endpoint
To evaluate the impact of missing data (as a result of early
discontinuation of treatment), three sensitivity analyses
were conducted for the primary efficacy endpoint: (a) a
generalized linear mixed model for repeated measures
(including factors for treatment group, week, and treatment
group 9 week); (b) a multiple imputation model using on-
treatment data; and (c) a multiple imputation model using
placebo data.
Secondary Endpoints
Secondary efficacy endpoints were assessed using an
analysis of covariance (ANCOVA) model with treatment
group, study number, number of CBMs per week at base-
line (0 or[0), geographical region, and sex as factors and
the baseline value of the outcome as a covariate. A Cox
proportional hazards regression model was used to com-
pare the time to first SBM and the time to first SCBM in the
prucalopride group versus the placebo group. The model
included terms for treatment group, study number, number
of CBMs per week at baseline (0 or [0), geographical
region, and sex. Hazard ratios and the respective 95 % CIs
and p values were obtained for each treatment group
comparison.
For PAC-SYM and PAC-QOL, descriptive statistics
(actual values and changes from baseline) for the total
score and subscale scores were performed at baseline and
at various time points during treatment. Similarly,
descriptive statistics were reported for global severity of
constipation (0 = absent to 4 = very severe) and global
efficacy of treatment (0 = not at all effective to 4 =
extremely effective).
The ANCOVA model used to compare treatment effects
included treatment group, study number, number of CBMs
per week at baseline (0 or[0), geographical region, and
sex as factors, and the baseline value of the outcome as a
covariate. PAC-SYM and PAC-QOL total scores and
subscale scores were also summarized by categories of
improvement (\1 point and C1-point of improvement from
baseline) and by treatment group. No statistical testing was
performed on these summaries.
Exploratory Analysis
The Cochran–Mantel–Haenszel test was used to compare
the proportions of patients meeting the primary endpoint
who had no SBMs at baseline with those who had one or
more SBMs at baseline.
Results
Overall, 2484 patients [597 (24 %) men] were included in
the integrated efficacy analysis: 1247 patients [300 (24 %)
men] received placebo and 1237 patients [297 (24 %) men]
received prucalopride B2 mg (Fig. 1; Table 2). The
majority of patients [2178 (87.7 %)] completed 12 weeks
of treatment. The main reasons for study discontinuation
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were adverse events (4.1 %), withdrawal of consent
(3.2 %), and lack of efficacy (1.5 %).
An overview of the demographics and baseline disease
characteristics of patients included in the integrated effi-
cacy population is presented in Table 2. Most patients were
Caucasian (75.5 %), and the mean [standard deviation
(SD)] age was 47.4 (15.6) years. The mean (SD) duration
of constipation was 16.5 (14.6) years. Overall, 30.0 % of
patients had no SBMs at baseline, consistent with severe
constipation. Demographics and baseline disease charac-
teristics were similar in the prucalopride and placebo
groups. However, there were some differences in demo-
graphics and baseline disease characteristics between men
and women (Table 3). Women were older on average than
men [56.3 (16.7) vs 45.0 (14.0) years], and the mean
duration of constipation was longer for women than for
men [18.8 (15.0) vs 11.6 (13.9) years]. There were also
differences between men and women in the frequencies of
the main complains reported at baseline; while the most
common main complaint in men and in women was
infrequent defecation (23.6 and 26.6 %, respectively), the
second most frequent main complaint was feeling not
completely empty in men (22.3 %), whereas in women it
was abdominal bloating (22.7 %).
Primary Efficacy Results
Overall, the percentage of patients with a mean frequency
of C3 SCBMs/week over the 12-week treatment period
was significantly higher (p\ 0.001) in the prucalopride
group (27.8 %) than the placebo group (13.2 %). The
difference in response rate between groups (the therapeutic
gain) was 14.6 %. The placebo response ranged from
9.6 % (PRU-INT-6) to 20.1 % (SPD555-401), and the
response to prucalopride ranged from 19.5 % (PRU-INT-6)
to 37.9 % (SPD555-302). During each individual week
from week 1 to week 12, the proportion of patients with
C3 SCBMs was always higher in the prucalopride group
than in the placebo group, with no evidence of decreasing
efficacy over time (Fig. 2).
Results were consistent when analyzed by sex, with the
therapeutic gain being similar in men (15.0 %) and women
(14.5 %) for the primary efficacy endpoint (both p\ 0.001
for the comparison of prucalopride vs placebo) (Fig. 3).
Furthermore, the proportion of patients with C3 SCBMs/
week was consistently higher in each of weeks 1–12 in the
prucalopride group than in the placebo group in both men
and women (Fig. 4). Interestingly, women had a peak in
response rate at week 1, which subsequently stabilized over
Fig. 1 Patient flow
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Table 2 Demographics and
baseline disease characteristics









Mean (SD) 47.4 (15.3) 47.5 (15.8) 47.4 (15.6)
Median (minimum, maximum) 47.0 (18, 91) 46.0 (17, 95) 47.0 (17, 95)
Age, n (%)
\65 years 1069 (85.7) 1041 (84.2) 2110 (84.9)
C65 years 178 (14.3) 196 (15.8) 374 (15.1)
Sex, n (%)
Men 300 (24.1) 297 (24.0) 597 (24.0)
Women 947 (75.9) 940 (76.0) 1887 (76.0)
Race, n (%)
Caucasian 951 (76.3) 925 (74.8) 1876 (75.5)
Non-Caucasian 287 (23.0) 303 (24.5) 590 (23.8)
Missing 9 (\1.0) 9 (\1.0) 18 (\1.0)
BMI (kg/m2)
Mean (SD) 24.8 (4.8) 25.1 (4.7) 25.0 (4.8)
Median (minimum, maximum) 24.0 (16, 65) 24.5 (15, 57) 24.2 (14, 65)
Duration of constipation, years
Mean (SD) 16.5 (14.5) 16.5 (14.8) 16.5 (14.6)
Median (minimum, maximum) 12.0 (1, 77) 10.2 (1, 70) 11.0 (1, 77)
Duration of constipation, years, n (%)
\1 42 (3.4) 33 (2.7) 75 (3.0)
1–\5 253 (20.3) 272 (22.0) 525 (21.1)
5–\10 179 (14.4) 157 (12.7) 336 (13.5)
10–\15 170 (13.6) 202 (16.3) 372 (15.0)
15–\20 98 (7.9) 101 (8.2) 199 (8.0)
C20 469 (37.6) 436 (35.2) 905 (36.4)
Missing 36 (2.9) 36 (2.9) 72 (2.9)
Main complaint, n (%)
Infrequent defecation 315 (25.3) 327 (26.4) 642 (25.8)
Abdominal bloating 263 (21.1) 239 (19.3) 502 (20.2)
Feeling of incomplete evacuation 205 (16.4) 212 (17.1) 417 (16.8)
Straining 185 (14.8) 174 (14.1) 359 (14.5)
Abdominal pain 161 (12.9) 162 (13.1) 323 (13.0)
Hard stools 118 (9.5) 122 (9.9) 240 (9.7)
Missing 0 1 (\1.0) 1 (\1.0)
SBMs/week during the last 6 months, n (%)
0 361 (28.9) 385 (31.1) 746 (30.0)
[0–B1 394 (31.6) 399 (32.3) 793 (31.9)
[1–B3 471 (37.8) 433 (35.0) 904 (36.4)
[3 21 (1.7) 20 (1.6) 41 (1.7)
Stools that are hard or very hard, n (%)
0–25 125 (10.0) 132 (10.7) 257 (10.3)
26–50 188 (15.1) 171 (13.8) 359 (14.5)
51–75 253 (20.3) 248 (20.0) 501 (20.2)
76–100 512 (41.1) 514 (41.6) 1026 (41.3)
Missing 169 (13.6) 172 (13.9) 341 (13.7)
Diet adjusted, n (%)
Yes 684 (54.9) 683 (55.2) 1367 (55.0)
No 563 (45.1) 554 (44.8) 1117 (45.0)
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the 12 weeks, whereas the response rate for men improved
slightly over weeks 1–12 (Fig. 4).
A forest plot comparing prucalopride with placebo for
the primary efficacy endpoint for each of the six clinical
trials and for the integrated (overall) population is pre-
sented in Fig. 5. The overall odds ratio was 2.68 (95 % CI
2.16–3.33). The number needed to treat (NNT) to achieve
the primary efficacy endpoint in one patient in the
prucalopride group was 8.8 (95 % CI 7.1–11.6).
Sensitivity Analyses
The results of three sensitivity analyses carried out for the
primary endpoint were consistent with the results of the
original analysis. The odds ratios (95 % CI) were 2.39
(2.16–2.65), 2.81 (2.27–3.48), and 2.77 (2.24–3.42) for the
generalized mixed model, the on-treatment multiple
imputation model, and the placebo multiple imputation
model, respectively (p\ 0.001 for all comparisons).
Heterogeneity
The Breslow–Day test for inconsistency of response rates
across trials resulted in a p value of 0.0406 and an I2
statistic of 56 %, indicating moderate heterogeneity. This
heterogeneity was due to the results of the SPD555-401
trial [22], which was conducted over 24 weeks as opposed
to 12 weeks. If these data were excluded, the I2 statistic
was 6.8 %, indicating no heterogeneity across the other
five clinical trials.
Secondary Efficacy Results
An overview of the main secondary efficacy endpoints is
presented in Table 4. There were significantly beneficial
results for the prucalopride group compared with the pla-
cebo group in the following outcomes: the proportion of
patients with a mean increase of C1 SCBM/week over the
12-week treatment period; the median time to first SCBM
after intake of investigational product on day 1; the
decrease in mean number of tablets of rescue medication
taken per week; the decrease in mean number of days of
rescue medication use over 12 weeks of treatment; the
mean improvement in PAC-SYM total score from baseline
to the final on-treatment assessment (with similar findings
observed for the stool, abdominal, and rectal symptom
subscale scores); and the mean improvement in PAC-QOL
total score from baseline to final on-treatment assessment.
The proportions of patients with an improvement of C1
point in the PAC-QOL subscale scores are presented in
Table 5.
When analyzed by sex, results were generally similar in
men and women (Table 6).
Exploratory Results
The odds ratio (95 % CI) for the proportion of patients with
no SBMs at baseline meeting the primary endpoint [3.16
(2.24–4.46)] was greater than that for patients with one or
more SBM at baseline [2.65 (1.98–3.55)]. However, the
magnitude of the difference between the placebo and
prucalopride groups in the proportion of patients meeting








Previous use of laxativesa, n (%)
Yes 867 (69.5) 873 (70.6) 1740 (70.0)
No 380 (30.5) 364 (29.4) 744 (30.0)
Previous use of bulk-forming laxativesa, n (%)
Yes 523 (41.9) 506 (40.9) 1029 (41.4)
No 724 (58.1) 731 (59.1) 1455 (58.6)
Overall therapeutic effect of laxatives/bulk-forming agents, n (%)
Adequate 191 (15.3) 198 (16.0) 389 (15.7)
Inadequate 907 (72.7) 904 (73.1) 1811 (72.9)
Missing 149 (11.9) 135 (10.9) 284 (11.4)
BMI body mass index, SBM spontaneous bowel movement, SD standard deviation
a In trial SPD555-401, these data were collected as part of prior and concomitant medications (no specific
questions were asked); in the other double-blind, placebo-controlled studies this was part of the baseline
disease characteristics information (specific yes/no questions were asked)
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(mean therapeutic gain for no SBMs vs one or more SBM
at baseline: 11.4 vs 15.1 %, respectively).
Safety
The overall mean (SD) duration of exposure was similar in
the prucalopride [87.3 (35.1) days] and placebo [87.9
(33.0) days] groups.
Demographic and Baseline Disease Characteristics
Overall, a total of 2552 patients (618 men) were included
in the integrated safety analysis; 1279 patients (309 men)
received placebo and 1273 patients (309 men) received
prucalopride B2 mg/day. The demographic characteristics
were similar to those of the efficacy analysis population
[78.2 % women, 79.5 % Caucasian, mean (SD) age
47.4 (15.2) years].
Table 3 Baseline disease characteristics of the pooled patient population analyzed by sex (efficacy analysis)













Main complaint, n (%)
Abdominal bloating 224 (23.7) 39 (13.0) 204 (21.7) 35 (11.8) 428 (22.7) 74 (12.4)
Abdominal pain 132 (13.9) 29 (9.7) 139 (14.8) 23 (7.7) 271 (14.4) 52 (8.7)
Feeling not completely empty 150 (15.8) 55 (18.3) 134 (14.3) 78 (26.3) 284 (15.1) 133 (22.3)
Hard stools 83 (8.8) 35 (11.7) 86 (9.1) 36 (12.1) 169 (9.0) 71 (11.9)
Infrequent defecation 240 (25.3) 75 (25.0) 261 (27.8) 66 (22.2) 501 (26.6) 141 (23.6)
Straining 118 (12.5) 67 (22.3) 116 (12.3) 58 (19.5) 234 (12.4) 125 (20.9)
Missing 0 0 0 1 (\1.0) 0 1 (\1.0)
Diet adjusted, n (%)
Yes 521 (55.0) 163 (54.3) 510 (54.3) 173 (58.2) 1031 (54.6) 336 (56.3)
No 426 (45.0) 137 (45.7) 430 (45.7) 124 (41.8) 856 (45.4) 261 (43.7)
Previous use of laxativesa, n (%)
Yes 677 (71.5) 190 (63.3) 683 (72.7) 190 (64.0) 1360 (72.1) 380 (63.7)
No 270 (28.5) 110 (36.7) 257 (27.3) 107 (36.0) 527 (27.9) 217 (36.3)
Previous use of bulk-forming laxativesa, n (%)
Yes 421 (44.5) 102 (34.0) 405 (43.1) 101 (34.0) 826 (43.8) 203 (34.0)
No 526 (55.5) 198 (66.0) 535 (56.9) 196 (66.0) 1061 (56.2) 394 (66.0)
SCBMs/week during the past 6 months, n (%)
0 321 (33.9) 40 (13.3) 329 (35.0) 56 (18.9) 650 (34.4) 96 (16.1)
[0–B1 310 (32.7) 84 (28.0) 309 (32.9) 90 (30.3) 619 (32.8) 174 (29.1)
[1–B3 308 (32.5) 163 (54.3) 294 (31.3) 139 (46.8) 602 (31.9) 302 (50.6)
[3 8 (\1.0) 13 (4.3) 8 (\1.0) 12 (4.0) 16 (\1.0) 25 (4.2)
Stools that are hard or very hard, n (%)
0–25 103 (10.9) 22 (7.3) 107 (11.4) 25 (8.4) 210 (11.1) 47 (7.9)
26–50 114 (12.0) 74 (24.7) 114 (12.1) 57 (19.2) 228 (12.1) 131 (21.9)
51–75 175 (18.5) 78 (26.0) 165 (17.6) 83 (27.9) 340 (18.0) 161 (27.0)
76–100 411 (43.4) 101 (33.7) 407 (43.3) 107 (36.0) 818 (43.3) 208 (34.8)
Missing 144 (15.2) 25 (8.3) 147 (15.6) 25 (8.4) 291 (15.4) 50 (8.4)
Overall therapeutic effect, n (%)
Adequate 159 (16.8) 32 (10.7) 162 (17.2) 36 (12.1) 321 (17.0) 68 (11.4)
Inadequate 672 (71.0) 235 (78.3) 679 (72.2) 225 (75.8) 1351 (71.6) 460 (77.1)
Missing 116 (12.2) 33 (11.0) 99 (10.5) 36 (12.1) 215 (11.4) 69 (11.6)
SCBM spontaneous complete bowel movement
a In trial SPD555-401, these data were collected as part of prior and concomitant medications (no specific questions were asked); in the other
double-blind, placebo-controlled studies this was part of the baseline disease characteristics information (specific yes/no questions were asked)
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Adverse Events
A summary of treatment-emergent adverse events (TEAEs)
in the pooled data set is presented in Table 7 by treatment
group. Overall, 806 patients (63.3 %) in the prucalopride
group and 682 patients (53.3 %) in the placebo group
experienced C1 TEAE. The majority of TEAEs experi-
enced by patients in both treatment groups were mild or
moderate in severity. No fatal TEAEs occurred. The most
common TEAEs (C5 %) in the prucalopride group were
gastrointestinal disorders (nausea, diarrhea, and abdominal
pain) and headache. Few patients reported cardiovascular
adverse events (Table 7).
Overall, fewer men than women reported C1 TEAE
(prucalopride group, 47.2 vs 68.5 %; placebo group, 38.5
vs 58.0 %, respectively). The most common TEAEs were
similar in both sexes, although the incidences of these
TEAEs tended to be lower in men than women in both
treatment groups (data not shown). Similar proportions of
men and women reported TEAEs leading to treatment
discontinuation (women: 5.4 % receiving prucalopride,
3.2 % receiving placebo; men: 4.5 % receiving prucalo-
pride, 3.9 % receiving placebo).
Clinical Laboratory Evaluations
Mean changes from baseline in biochemistry, hematology,
and urinalysis parameters were generally small and were
not considered to be clinically relevant (data not shown).
The incidence of TEAEs related to laboratory test abnor-
malities was generally low and was similar in the
prucalopride and placebo groups as well as in men and
women (data not shown).
Vital Signs and ECG Parameters
Mean values and mean changes from baseline for ECG
parameters in the pooled population are provided in
Fig. 3 Proportion of patients in the pooled population with a mean
frequency of C3 spontaneous complete bowel movements per week
over the 1–12-week treatment period analyzed by sex. *p\ 0.001
versus placebo
Fig. 2 Proportion of patients in the pooled population with a mean
frequency of C3 spontaneous complete bowel movements/week over
the 12-week treatment period, by individual weekly period
Fig. 4 Proportion of a women and b men in the pooled population
with a mean frequency of C3 spontaneous complete bowel move-
ments per week over the 12-week treatment period analyzed by
individual weekly period
Dig Dis Sci (2016) 61:2357–2372 2365
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Table 8 by treatment group. Mean changes from baseline
in ECG (mean change from baseline \1 ms, with two
standard deviations \50 ms, with the mean baseline
415 ms) and vital sign parameters were generally small and
were not considered to be clinically relevant. The inci-
dences of TEAEs related to ECG and vital sign abnor-
malities were generally low and were similar in the
prucalopride B2 mg/day and placebo groups as well as in
men and women. The proportion of patients who experi-
enced any adverse cardiovascular events was low and
comparable between groups (1.8 % for placebo vs 2.0 %
for prucalopride). None of the individual TEAEs were
reported for[1 % of patients in either sex in either treat-
ment group. One patient (\1 %) in the placebo group, and
no patients in the prucalopride group, experienced angina
pectoris; one patient in each of the placebo and prucalo-
pride groups (\1 % for both) experienced myocardial
ischemia.
Discussion
The findings of this integrated analysis of six double-blind,
randomized, placebo-controlled, phase 3 and 4 trials con-
firm that prucalopride is an effective treatment for adults
with CC. Over the 12-week treatment period, significantly
more patients in the prucalopride group than in the placebo
group achieved a mean of C3 SCBMs/week. These results
are consistent with the treatment response observed in the
individual trials [18–21], with the exception of the
SPD555-401 trial, which failed to demonstrate a statisti-
cally significant effect of prucalopride on this primary
endpoint after both 12 and 24 weeks of treatment. An
extensive evaluation of the SPD555-401 trial has been
unable to provide an explanation for the reported lack of
efficacy [22, 23].
Overall results in the current study were similar for men
and women, although there was a difference in the response
rate over time between the sexes. This could be related to
differences in demographics (other than gender) and dis-
ease characteristics at baseline, or to intrinsic differences in
responsiveness to prucalopride between men and women.
Furthermore, prucalopride was significantly more effica-
cious than placebo as assessed by a variety of secondary
endpoints, including improvements in PAC-SYM and
PAC-QOL scores and rescue medication use. An explora-
tory efficacy analysis indicated that even patients with very
severe CC—those with no SBMs at baseline—benefited
from prucalopride treatment.
The findings of this integrated analysis confirm and
extend (with the addition of three trials [21–23]) the results
of a recent systematic review and meta-analysis, which
demonstrated the efficacy of a number of highly selective
5-HT4 receptor agonists, including prucalopride, in the
treatment of patients with CC [25]. Efficacy was evaluated
on the basis of several important clinical outcomes (BM
frequency, stool consistency, constipation-related quality
of life, and symptom scores) [25]. The results of this
analysis were also similar to those of two separate inte-
grated analyses involving only women [26, 27]. The pre-
sent integrated analysis differed from the previous analyses
with regard to the inclusion of the male patient population
from the SPD555-302 study, allowing meaningful com-
parison to be made of the response of men and women to
prucalopride treatment [25–27]. Prucalopride showed a
consistent treatment effect in both sexes.
Several novel therapeutic options are available for treat-
ment of men and women with CC. These typically target two
physiological processes: motility and secretion. Gastroin-
testinal motility is regulated in part by high-amplitude
propagating contractions (HAPCs), which occur, on aver-
age, six times per day in healthy individuals—particularly
immediately after awakening and after meals [28, 29].
Fig. 5 Forest plot comparing
prucalopride with placebo for a
frequency of C3 spontaneous
complete bowel movements per
week for each of the phase 3 and
4 clinical trials and for the
integrated (pooled) patient
population. Breslow–Day test
for inconsistency of response
rates between studies resulted in
a p value of 0.0406 and an I2
statistic of 56 %, indicating a
moderate heterogeneity. CI
confidence interval, OR odds
ratio
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Table 4 Overview of the main secondary efficacy endpoints in the pooled patient population





Na Value Na Value
Increase in SCBM frequency, n (%)
Proportion of patients with a mean
increase of C1 SCBM/week
Weeks 1–12 1247 373 (29.9) 1237 582 (47.0) \0.001b
Stool characteristics
Proportion of stools with normal
consistency, mean %
Run-in 1238 25.1 1230 24.9
Weeks 1–12 1214 38.5 1181 43.3 NA
Proportion of stools with hard to very
hard consistency, mean %
Run-in 1238 45.5 1230 45.3
Weeks 1–12 1214 34.3 1181 25.4 NA
Proportion of stools with no straining,
mean %
Run-in 1238 15.1 1230 15.3
Weeks 1–12 1214 16.6 1181 20.8 NA
Proportion of stools with severe or very
severe straining, mean %
Run-in 1238 33.0 1230 34.1
Weeks 1–12 1214 24.8 1181 18.8 NA
Time to first SCBM, days, median (95 %
CI)
Time from day 1 1247 13.5 (12.0–16.0) 1237 3.1 (2.5–3.7) \0.001c
Rescue medication use, mean (mean change)
Number of laxatives (tablets) taken/
week
Run-in 1241 1.9 1232 1.8
Weeks 1–12 1150 1.5 (–0.3) 1142 0.9 (–0.9) \0.001d
Number of days with rescue medication
use/week
Run-in 1241 1.0 1232 0.9
Weeks 1–12 1150 0.7 (–0.2) 1142 0.4 (–0.5) \0.001d
PAC-SYM score, mean (mean change)
Total score Baseline 1240 1.9 1234 1.9
FoTA 1228 1.4 (–0.4) 1212 1.2 (–0.7) \0.001d
Stool symptoms Baseline 1239 2.4 1233 2.4
FoTA 1228 1.9 (–0.5) 1212 1.6 (–0.8) \0.001d
Abdominal symptoms Baseline 1240 1.8 1233 1.8
FoTA 1227 1.3 (–0.4) 1213 1.1 (–0.7) \0.001d
Rectal symptoms Baseline 1236 1.1 1232 1.2
FoTA 1227 0.8 (–0.3) 1212 0.7 (–0.5) \0.001d
PAC-SYM score, patients with an improvement of C1 point from baseline, n (%)
Total score FoTA 1221 292 (23.9) 1209 402 (33.3) NA
Stool symptoms FoTA 1220 395 (32.4) 1208 526 (43.5) NA
Abdominal symptoms FoTA 1220 344 (28.2) 1209 460 (38.0) NA
Rectal symptoms FoTA 1216 299 (24.6) 1207 376 (31.2) NA
PAC-QOL score, mean (mean change)
Total score Baseline 1238 2.1 1233 2.0
FoTA 1210 1.6 (–0.5) 1206 1.3 (–0.7) \0.001d
PAC-QOL score, patients with an improvement of C1 point from baseline, n (%)
Total score FoTA 1201 268 (22.3) 1202 446 (37.1) NA
Global assessment of severity of constipation, mean (mean change)
Baseline 1236 2.7 1232 2.7
12 weeks 1075 2.2 (–0.6) 1078 1.7 (–1.0) NA
Global assessment of efficacy of treatment, mean
12 weeks 1075 1.3 1077 1.9 NA
ANCOVA analysis of covariance, CBM complete bowel movement, CI confidence interval, FoTA final on-treatment assessment, NA not assessed,
PAC-QOL Patient Assessment of Constipation Quality of Life questionnaire, PAC-SYM Patient Assessment of Constipation Symptoms ques-
tionnaire, SCBM spontaneous complete bowel movement
a Number with data for each endpoint
b p value based on a Cochran–Mantel–Haenszel test controlling for study number, sex, geographical region, and number of CBMs/week at
baseline
c p value based on a Cox proportional hazard regression including terms for treatment group, study number, geographical region, number of
CBMs at baseline (0 or[0), and sex
d p value based on an ANCOVA model performed with study number, geographical region, number of CBMs/week during the run-in period (0 or
[0), and sex as factors and the baseline value of the outcome as a covariate
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HAPCs result in mass movement of colonic contents, and
are often followed by an urge to defecate [28]. In patients
with CC, the frequency and duration of HAPCs are reduced
in comparison with healthy individuals [30]. Prucalopride
has been shown to stimulate gastrointestinal motility,
including accelerating gastric, proximal colonic, and colonic
transit [31]. Therefore, prucalopride may be particularly
beneficial for patients with CC who have a paucity of
HAPCs, or in those who do not respond to other medications.
Secretagogues, such as lubiprostone or linaclotide, exert
their effects by increasing intestinal and colonic secretion of
chloride-rich fluid into the intestinal lumen [32]; there is no
reported evidence that these agents induce HAPCs; this was
specifically tested with lubiprostone in comparison with
placebo during fasting and postprandially in healthy human
volunteers [33].
In the current integrated analyses, the NNT with
prucalopride to achieve the primary efficacy endpoint in
one patient was 8.8 (95 % CI 7.1–11.6). In a meta-analysis
of data from three trials of linaclotide in patients with CC,
the NNT for the primary endpoint of these trials
([3 SCBMs/week and an increase of C1 SCBM/week, for
75 % of weeks) was 7 (95 % CI 5–8) [34].
Other selective 5-HT4 receptor agonists have been
evaluated for the treatment of patients with CC: velusetrag,
naronapride, and YKP10811 [35–38]. However, trials of
these agents have, to date, been relatively small phase 2
studies or pharmacodynamic studies in healthy volunteers;
the current integrated analysis provides the most robust
evidence that this class of medication, and particularly
prucalopride, is efficacious in the treatment of patients with
CC.
There has been considerable interest in the safety profile
of 5-HT4 receptor agonists in development, owing to the
apparent association of the non-selective 5-HT4 receptor
agonists tegaserod and cisapride with cardiovascular
adverse events [39, 40]. The results of this integrated
analysis show that prucalopride has a favorable safety and
tolerability profile. This is consistent with the findings of
two previous studies that focused on assessment of the
safety of prucalopride [41, 42]. Of particular interest, no
cardiovascular safety signals were identified; specifically,
the mean QT interval corrected according to Bazett’s
formula (QTcB) and the mean QT interval corrected
according to Fridericia’s formula (QTcF) were both
\470 ms.
A potential limitation of this integrated analysis is that
the results of one of the six trials deviated from those of
the other trials for reasons that are not clear, causing
moderate heterogeneity (I2 = 56 %). However, the
results of the other five trials, involving 86 % of
patients, were highly homogeneous (I2 = 6.8 %). Fur-
thermore, homogeneity was demonstrated across trials
conducted in Asian, American, and European popula-
tions, confirming the validity of the results of the inte-
grated analysis.
In conclusion, in this integrated analysis of over
2000 patients from four continents, prucalopride was
demonstrated to be efficacious in the treatment of
individuals with CC. Prucalopride was also shown to
have a favorable safety and tolerability profile, with no
cardiovascular adverse event concerns. Efficacy and
safety findings were consistent in both men and
women.
Table 5 Proportion of patients with an improvement of C1 point in the PAC-QOL subscale scores in the pooled population
PAC-QOL subscale Patients with an improvement of C1 point from baseline to final on-treatment assessment, n (%)
Placebo
N = 1247
Prucalopride B 2 mg
N = 1237
Na Value Na Value
Dissatisfaction 1192 316 (26.5) 1198 554 (46.2)
Physical discomfort 1202 404 (33.6) 1202 568 (47.3)
Psychosocial discomfort 1196 267 (22.3) 1201 327 (27.2)
Worries and concerns 1198 314 (26.2) 1201 474 (39.5)
PAC-QOL Patient Assessment of Constipation Quality of Life questionnaire
a Number with data for each endpoint
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Table 6 Overview of secondary efficacy endpoints analyzed by sex in the pooled patient population
Endpoint Time
period
Placebo Prucalopride B 2 mg
Women, N = 947 Men, N = 300 Women, N = 940 Men, N = 297
Na Value Na Value Na Value p value Na Value p value
Increase in SCBM frequency, n (%)
Proportion of patients
with a mean increase of
C1 SCBM/week
Week 1–12 947 256 (27.0) 300 117 (39.0) 940 444 (47.2) \0.001b 297 138 (46.5) 0.025b
Stool characteristic (mean %)
Proportion of stools with
normal consistency
Run-in 942 24.4 296 27.3 937 24.6 NA 293 25.8 NA
Week 1–12 924 36.3 290 45.6 899 43.1 NA 282 44.1 NA
Proportion of stools with
hard to very hard
consistency
Run-in 942 44.6 296 48.5 937 43.4 NA 293 51.3 NA
Week 1–12 924 35.4 290 30.9 899 25.3 NA 282 25.7 NA
Proportion of stools with
no straining
Run-in 942 16.7 296 10.1 937 17.7 NA 293 7.5 NA
Week 1–12 924 17.7 290 13.0 899 22.8 NA 282 14.2 NA
Proportion of stools with
severe or very severe
straining
Run-in 942 32.6 296 34.3 937 32.0 NA 293 40.9 NA
Week 1–12 924 25.7 290 21.9 899 18.5 NA 282 19.7 NA
Time to first SCBM, days,












Rescue medication use, mean (mean change)
Number of laxatives
(tablets) taken/week
Run-in 945 2.0 296 1.8 939 1.9 293 1.6
Week 1–12 872 1.7 (–0.2) 278 1.1 (–0.6) 869 1.0 (–0.9) \0.001d 270 0.8 (–0.8) 0.019d
Number of days with
rescue medication use/
week
Run-in 945 1.0 296 1.0 939 0.9 293 0.9
Week 1–12 872 0.8 (–0.2) 275 0.6 (–0.4) 869 0.5 (–0.5) \0.001d 270 0.4 (–0.5) 0.007d
PAC-SYM score, mean (mean change)
Total score Baseline 944 1.9 296 1.7 939 1.9 295 1.8
FoTA 938 1.5 (–0.4) 290 1.2 (–0.5) 927 1.2 (–0.7) \0.001d 285 1.1 (–0.7) 0.019d
PAC-SYM score, patients with an improvement of C1 point from baseline, n (%)
Total score FoTA 935 222 (23.7) 286 70 (24.5) 926 314 (33.9) NA 283 88 (31.1) NA
PAC-QOL score, mean (mean change)
Total score Baseline 941 2.1 297 1.9 938 2.1 295 1.9
FoTA 922 1.7 (–0.4) 288 1.4 (–0.5) 921 1.3 (–0.8) \0.001d 285 1.2 (–0.7) 0.003d
PAC-QOL score, patients with an improvement of C1 point from baseline, n (%)
Total score FoTA 916 190 (20.7) 285 78 (27.4) 919 346 (37.6) NA 283 100 (35.3) NA
ANCOVA analysis of covariance, CBM complete bowel movement, CI confidence interval, FoTA final on-treatment assessment, NA not
available, PAC-QOL Patient Assessment of Constipation Quality of Life questionnaire, PAC-SYM Patient Assessment of Constipation Symptoms
questionnaire, SCBM spontaneous complete bowel movement
a Number with data for each endpoint
b p value based on a Cochran–Mantel–Haenszel test controlling for study number, sex, geographical region, and number of CBMs/week at
baseline
c p value based on a Cox proportional hazard regression including terms for treatment group, study number, geographical region, number of
CBMs at baseline (0 or[0), and sex
d p value based on an ANCOVA model performed with study number, country, number of CBMs/week (0 or[0) during the run-in period, and
sex as factors and the baseline value of the outcome as a covariate
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the pooled patient population
TEAEs Placebo, n (%)
N = 1279
Prucalopride B 2 mg/day, n (%)
N = 1273
At least one TEAE 682 (53.3) 806 (63.3)
TEAEs related to the investigational product 272 (21.3) 461 (36.2)
Mild TEAEs 471 (36.8) 585 (46.0)
Moderate TEAEs 358 (28.0) 418 (32.8)
Severe TEAEs 113 (8.8) 152 (11.9)
Serious TEAEs 31 (2.4) 21 (1.6)
Fatal TEAEs 0 0
TEAEs leading to permanent discontinuation 43 (3.4) 66 (5.2)
TEAEs of cardiovascular interest
Angina pectoris 1 (\0.1) 0
Unstable angina 0 0
Myocardial infarction 0 0
Myocardial ischemia 1 (\0.1) 1 (\0.1)
Cerebrovascular accident 0 1 (\0.1)
Ischemic stroke 1 (\0.1) 0
TEAE treatment-emergent adverse event
Table 8 ECG results in the pooled patient population
Parameter Placebo, N = 1279 Prucalopride B2 mg/day, N = 1273
Mean (SD) Mean (SD) change from baseline Mean (SD) Mean (SD) change from baseline
Heart rate (bpm)
Baseline 66.4 (10.48) 66.9 (10.37)
Week 12 68.2 (11.11) 1.5 (9.60) 68.6 (10.30) 1.8 (9.21)
PR interval (ms)
Baseline 158.3 (26.11) 157.9 (25.69)
Week 12 156.7 (24.01) –0.9 (16.46) 154.1 (22.61) –3.2 (16.13)
QRS interval (ms)
Baseline 88.4 (13.94) 88.5 (14.29)
Week 12 86.7 (13.69) –0.4 (9.71) 87.9 (13.79) 0.2 (8.88)
QT interval (ms)
Baseline 396.6 (33.79) 393.9 (34.01)
Week 12 391.4 (33.51) –4.1 (26.64) 389.8 (31.52) –4.1 (26.85)
QTcB (ms)
Baseline 414.3 (27.60) 413.7 (30.11)
Week 12 414.1 (27.23) 0.3 (24.36) 414.5 (26.89) 1.2 (24.76)
QTcF (ms)
Baseline 408.0 (23.90) 406.7 (27.93)
Week 12 406.1 (25.38) –1.2 (21.33) 405.9 (24.83) –0.6 (22.16)
bpm beats/min, ECG electrocardiogram, QTcB QT interval corrected according to Bazett’s formula, QTcF QT interval corrected according to
Fridericia’s formula, SD standard deviation
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